KIT UBI trap-A for Western-blot 

Product Description

UBI traps are used to isolate and identify ubiquitylated proteins from cells, tissues or organs. Multiple ubiquitin binding domains (UBDs) contribute to enhance their affinity for polyubiquitin chains compared to single UBD.  (1-3). Prototype UBI traps interfere with the action of de-ubiquitylating enzymes (DUBs) and the proteasome which contribute to increase the yield of ubiquitylated proteins purified and facilitate the detection of low abundance proteins. These unique properties are not observed with any other technologies that can be used in a large panel of applications (3). 

UBI trap-B is based on UBDs with preference for K63 linked polyubiquitin chains but other chains can also be captured (1-3). Furthermore, differences can be observed depending on the relative chain abundance in distinct cell lines and response to various treatments.  GST control is provided for a single control reaction. KIT UBI trap-B contains all reagents and solutions required for the capture of Ubiquitylated proteins from cell lines, tissues and organs (see below). 

Characteristics

Tag: GST

Purity: > 95% by RP-HPLC and SDS-PAGE

Molecular Weight: 55,647      kDa

Physical State: Liquid

Quantity: 200 µg      

Solubility: >30 mg/mL

Concentration: Variable (5-10 mg/mL     )

Storage: -80°C, avoid freeze/thaw cycles

Application

Pull down of poly-ubiquitylated proteins from cell and tissue lysates using glutathione beads. Captured proteins can be analyzed by Western blot or Mass spectrometry with the appropriate adaptations. 

Protection of poly-ubiquitylated proteins from both deubiquitylation and degradation by the proteasome

Quantitative or semiquantitative methods using different supports. 

Benefits

Up to 1000-fold higher affinity than the single UBD

Avoid overexpression of tagged ubiquitin for pull downs

Protect poly-ubiquitin chains without inhibitors specific to the proteasome or DUBs activity

Replace ubiquitin specific antibodies for enrichment of poly-ubiquitylated proteins

Examples of use

UBI trap-B can be used to detect ubiquitylated cellular factors implicated in the regulation of signaling pathways regulating inflammation, oncogenesis, neurodegenerative diseases and multiple infections (4-8). The ubiquitylated status of these factors can be followed in response to a treatment and determine if cells are responding well (9-10). The ubiquitylation of crucial cellular factors can also be followed after infection with various microorganisms (11). Among other examples. A UBI traps step by step protocol has also been      reported (12).

Publications

(1) Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, England P, Rodriguez MS.EMBO Rep. 2009 Nov;10(11):1250-8. 

(2) Polyubiquitin-sensor proteins reveal localization and linkage-type dependence of cellular ubiquitin signaling. Sims JJ, Scavone F, Cooper EM, Kane LA, Youle RJ, Boeke JD, Cohen RE.Nat Methods. 2012 Feb 5;9(3):303-9.

(3) Using Ubiquitin Binders to Decipher the Ubiquitin Code. Mattern M, Sutherland J, Kadimisetty K, Barrio R, Rodriguez MS.Trends Biochem Sci. 2019 Jul;44(7):599-615. 

(4)Role of monoubiquitylation on the control of IκBα degradation and NF-κB activity.  Da Silva-Ferrada E, Torres-Ramos M, Aillet F, Campagna M, Matute C, Rivas C, Rodríguez MS, Lang V. PLoS One. 2011;6(10):e25397. 

(5) Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity. Lang V, Pallara C, Zabala A, Lobato-Gil S, Lopitz-Otsoa F, Farrás R, Hjerpe R, Torres-Ramos M, Zabaleta L, Blattner C, Hay RT, Barrio R, Carracedo A, Fernandez-Recio J, Rodríguez MS, Aillet F. Mol Oncol. 2014 Jul;8(5):1026-42. 

(6) Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3-ITD-driven acute myeloid leukemia.  Lopez-Reyes RG, Quinet G, Gonzalez-Santamarta M, Larrue C, Sarry JE, Rodriguez MS. FEBS Open Bio. 2021 Jan;11(1):48-60. 

(7) Analysis of defective protein ubiquitylation associated to adriamycin resistant cells. Lang V, Aillet F, Xolalpa W, Serna S, Ceccato L, Lopez-Reyes RG, Lopez-Mato MP, Januchowski R, Reichardt NC, Rodriguez MS. Cell Cycle. 2017;16(24):2337-2344.

(8) Activation of AHR mediates the ubiquitination and proteasome degradation of c-Fos through the induction of Ubcm4 gene expression. Mejía-García A, González-Barbosa E, Martínez-Guzmán C, Torres-Ramos MA, Rodríguez MS, Guzmán-León S, Elizondo G. Toxicology. 2015 Nov 4;337:47-57. 

(9) Activation of aryl hydrocarbon receptor regulates the LPS/IFNgamma-induced inflammatory response by inducing ubiquitin-proteosomal and lysosomal degradation of RelA/p65.  Domínguez-Acosta O, Vega L, Estrada-Muñiz E, Rodríguez MS, Gonzalez FJ, Elizondo G. Biochem Pharmacol. 2018 Sep;155:141-149. 

(10) Efficient monitoring of protein ubiquitylation levels using TUBEs-based microarrays. Serna S, Xolalpa W, Lang V, Aillet F, England P, Reichardt N, Rodriguez MS.FEBS Lett. 2016 Aug;590(16):2748-56. 

14;14:200.

(11) New insights into host-parasite ubiquitin proteome dynamics in P. falciparum infected red blood cells using a TUBEs-MS approach. Mata-Cantero L, Azkargorta M, Aillet F, Xolalpa W, LaFuente MJ, Elortza F, Carvalho AS, Martin-Plaza J, Matthiesen R, Rodriguez MS.J Proteomics. 2016 Apr 29;139:45-59. 

(12) Isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. Aillet F, Lopitz-Otsoa F, Hjerpe R, Torres-Ramos M, Lang V, Rodríguez MS.Methods Mol Biol. 2012;832:173-83.